Bumetanide Injection Shortage: Current Availability and Manufacturer Updates
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Bumetanide Injection, a cardiovascular medication, remains on the FDA shortage list, though several manufacturers currently report product availability.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Bumetanide.
What's in Shortage
Bumetanide Injection (brand name: BUMETANIDE) is currently listed on the FDA drug shortage database. This medication is an injection used within the cardiovascular therapeutic category. While the shortage status is listed as "Current," several manufacturers have recently reported that their specific presentations are available.
This shortage was first posted on January 31, 2018, and the most recent update was provided on February 3, 2026.
Which Manufacturers Are Affected
Several manufacturers supply Bumetanide Injection. Their current status and contact information are as follows:
Sagent Pharmaceuticals
- Status: Available
- Presentations: .25 mg/1 mL (NDC 25021-321-10 and NDC 25021-321-04)
- Contact: 866-625-1618
Fresenius Kabi USA, LLC
- Status: Available (Note: The manufacturer advises checking wholesalers for current inventory)
- Presentations: .25 mg/1 mL (NDC 65219-570-04 and NDC 65219-572-10)
- Contact: 888-386-1300
MSN Laboratories Private Limited (Distributed by Novadoz Pharmaceuticals LLC)
- Status: Available
- Presentations: .25 mg/1 mL (NDC 72205-101-07 and NDC 72205-102-07); 0.25 mg/mL in 4 mL (NDC 72205-101-01); 0.25 mg/mL in 10 mL (NDC 72205-102-01)
- Contact: 855-668-2369 or customerservice@novadozpharma.com
Why There's a Shortage
The FDA source data does not provide a specific reason for the ongoing shortage of Bumetanide Injection.
What Patients Should Do
If you or a loved one relies on Bumetanide Injection, please consider the following steps:
- Consult Your Healthcare Provider: Always speak with your doctor regarding your treatment plan. Do not make changes to your medication without professional medical guidance.
- Speak with Your Pharmacist: Pharmacists often have the most up-to-date information on which wholesalers have stock available.
- Contact Manufacturers: If you are having difficulty locating the medication, you may use the contact information provided above to inquire about supply distribution.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare provider for all medical decisions and alternative treatment options.
Source
Information provided by the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.